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Doxorubicin induces DNA damage to exert its anti-cancer function. Histone deacetylase 1 (HDAC1)
can protect the genome from DNA damage. We found that doxorubicin speciﬁcally downregulates
HDAC1 protein expression and identiﬁed HDAC1 as a target of miR-520h, which was upregulated
by doxorubicin. Doxorubicin-induced cell death was impaired by exogenous HDAC1 or by miR-
520h inhibitor. Moreover, HDAC1 reduced the level of cH2AX by preventing the interaction of doxo-
rubicin with DNA. In summary, doxorubicin downregulates HDAC1 protein expression, by inducing
the expression of HDAC1-targeting miR-520h, to exacerbate DNA–doxorubicin interaction. The
upregulation of HDAC1 protein may contribute to drug resistance of human cancer cells and target-
ing HDAC1 is a promising strategy to increase the clinical efﬁcacy of DNA damage-inducing chemo-
therapeutic drugs.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Gastric cancer remains one of the leading causes of cancer-re-
lated mortality. Doxorubicin-containing systemic chemotherapy
is the preferential treatment option for gastric cancer [1]. As an
anthracycline anticancer drug, doxorubicin exerts its anti-cancer
action due to its interaction into double strand DNA and its role
of DNA topoisomerase II inhibitor. DNA double strand breaks are
induced by DNA–doxorubicin interaction, consequently accelerate
cancer cell death. The structures of the DNA-anthracycline com-
plexes have been revealed by X-ray diffraction method [2]. The
anthraquinone ring of doxorubicin is sandwiched between two
neighboring base pairs, following a formation of an extra space be-
tween these two base pairs [3]. Recently doxorubicin was found to
bind DNA minor groove to disturb double strand structure of DNA
[4,5]. The out-binding pattern offers a feasible explanation for the
intricate dynamics observed in the doxorubicin–DNA studies.
Despite its wide clinical application, acquired or intrinsic resis-
tance and severe cardiac toxicity during chemotherapy often leads
to the failure of doxorubicin-based treatments. Substantial efforts
have been made to overcome drug resistance or improve side
effects of doxorubicin.Histone deacetylase (HDAC) family proteins modulate chroma-
tin condensation and transcriptional repression [6]. Besides, his-
tone acetylation is important to DNA double strand break repair
[7]. HDAC1- and 2-depleted cells were hypersensitive to DNA-
damage [8]. All of these ﬁndings indicate a potential relevance of
HDACs to the DNA damage induction and anti-cancer effect of
doxorubicin. Indeed, Phase I/II clinical studies on combined HDACi
(histone deacetylase inhibitor) and doxorubicin have found poten-
tial superiority on effectiveness in the treatment of various cancer
such as mesothelioma [9], non-Hodgkin’s lymphoma [10], breast
cancer [11] and other advanced solid tumors [12,13]. However,
how HDACs inﬂuence DNA damage induction and anti-cancer
effect of doxorubicin remained unclariﬁed.
In this report, we found that HDAC1 protein was down-regu-
lated by doxorubicin in gastric cancer cells. However, doxorubicin
affects neither protein stability nor mRNA level of HDAC1. We fur-
ther deﬁned HDAC1 as a target of miR-520h which was markedly
upregulated after doxorubicin treatment. The viability inhibitory
effect of doxorubicin was impaired in the presence of exogenous
HDAC1 expression or when doxorubicin-induced HDAC1 protein
down-regulation was blocked by miR-520h inhibitors. Moreover,
HDAC1 reduced DNA damage by attenuating the interaction of
doxorubicin with double strand DNA. Therefore, doxorubicin exac-
erbates DNA damage by epigenetically down-regulating HDAC1
protein expression.
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2.1. Doxorubicin down-regulates HDAC1 protein expression in gastric
cancer cells
As expected, doxorubicin inhibited the viability of human gas-
tric cancer cell lines MKN45 and MKN28 in a dose-dependent man-
ner (Fig. 1A and B). Next, we wonder whether doxorubicin has any
effects on the expression of HDACs. Interestingly, HDAC1 protein
expression was remarkably reduced after 4 lM doxorubicin treat-
ment for 8 h (Fig. 1C). However, the expression of other HDACs
such as HDAC2, 3 and 8 were not affected by doxorubicin
(Fig. 1C). Furthermore, we found that doxorubicin-induced HDAC1
protein down-regulation started at 4–6 h after 4 lM doxorubicin
treatment (Fig. 1D and E), suggesting that doxorubicin probably
did not affect the stability of HDAC1 protein.
2.2. Doxorubicin did not reduce HDAC1 protein stability or decrease its
mRNA level
Indeed, treatment with 10 lM or 20 lM MG132 for 9 h, a
widely used inhibitor of ubiquitin–proteasome system, cannot
rescue the down-regulation of HDAC1 protein caused by doxorubi-
cin in MKN45 and MKN28 cells (Fig. 2A). In addition to ubiquitin–
proteasome system, autophagy–lysosome system was another
important pathway of protein degradation. However, the treat-
ment of 50 nM autophagy inhibitor chloroquine (CQ) for 24 h has
no inﬂuence on the down-regulation of HDAC1 protein caused by
doxorubicin (Fig. 2B). To further ascertain whether the HDAC1 is
down-regulated at post-translational level, Flag-tagged HDAC1
expressing plasmid was transfected into MKN45 cells. The levels
of exogenous Flag-HDAC1 protein expression were not affectedFig. 1. HDAC1 expression was down-regulated in gastric cancer cells after doxorubicin tr
MKN45 (A) andMKN28 cells (B) were determined by MTS assay. (C) The expression of oth
doxorubicin for 8 h were analyzed by Western blot analysis. The numbers under the blot
cells (D) and MKN28 cells (E) treated with 4 lM doxorubicin were analyzed by Westernby 4 lM doxorubicin (Fig. 2C), suggesting that doxorubicin did
not induce the degradation of HDAC1 protein.
Since the level of mRNA could also inﬂuence protein expression,
real time RT-PCR was performed to detect HDAC1 mRNA expres-
sion in MKN45 and MKN28 cells before and after doxorubicin
treatment. Interestingly, HDAC1 mRNA was not down-regulated
after the same doxorubicin treatment (Fig. 2D). These results indi-
cated that doxorubicin did not inhibit HDAC1 expression at the
transcriptional level.
2.3. Doxorubicin down-regulates HDAC1 protein by inducing
miR-520h expression
MicroRNA (miRNA) could affect gene expression by regulating
mRNA translation efﬁciency, thus regulating gene expression at a
post-transcriptional but pre-translational level. Therefore, we
wonder whether doxorubicin affects HDAC1 through miRNA. Sev-
eral prediction tools such as Targetscan and PicTar were used to
search miRNAs potential regulating HDAC1. Among these miRNAs,
only miR-520h was dramatically upregulated after 4 lM doxorubi-
cin treatment in MKN45 cells so that we focused on miR-520h in
the following studies (Fig. 3A). First, we conﬁrmed its up-regula-
tion in both MKN45 and MKN28 cells upon doxorubicin treatment
(Fig. 3B). In addition, 50 nM miR-520h inhibitor rescued doxorubi-
cin-induced down-regulation of HDAC1 in both MKN45 and
MKN28 cells (Fig. 3C). Furthermore, 10 nM and 20 nM miR-520h
mimics down-regulated HDAC1 expression in both cell lines
(Fig. 3D). These results demonstrated that doxorubicin affects
HDAC1 expression through upregulation of miR-520h. The dual
luciferase reporter system was utilized to further clarify whether
HDAC1 is the direct target of miR-520h. The 30-UTR of the HDAC1
gene that contains a complementary binding site for miR-520h waseatment. The viability inhibitory effect of doxorubicin on human gastric cancer cells
er HDACs (HDACs 1, 2, 3, and 8) in MKN45 cells and MKN28 cells cultured with 4 lM
indicate its relative laser densitometric quantiﬁcation. HDAC1 expression in MKN45
blot analysis. All experiments were repeated three times.
Fig. 2. Expression of HDAC1 is not down-regulated at post-translational level or transcriptional level in human gastric cancer cells after doxorubicin treatment. HDAC1
expression in MKN45 cells preincubated with 10 lM or 20 lM MG132 for 9 h (A) or 50 nM CQ for 24 h (B) before doxorubicin treatment was determined by Western blot
analysis. (C) The expression of exogenous HDAC1, by transfected with Flag-HDAC1 expressing plasmid in MKN45 cells, after doxorubicin treatment was analyzed by Western
blotting. (D) HDAC1 mRNA level in MKN45 cells and MKN28 cells cultured with 4 lM doxorubicin for 8 h was analyzed by real-time RT-PCR. All experiments were repeated
three times.
Fig. 3. Down-regulation of HDAC1 induced by doxorubicin was mediated by miR-520h. (A) Potential miRNAs selected by target-prediction tools were screened by real-time
RT-PCR analysis of their expression in MKN45 cells after doxorubicin treatment as above mentioned. (B) MiR-520h expression in MKN45 and MKN28 cells after 4 lM
doxorubicin treatment for 8 h was analyzed by real-time RT-PCR. (C) Western blot analysis of HDAC1 expression in MKN45 cells and MKN28 cells preincubated with 50 nM
miR-520h inhibitor 48 h before doxorubicin treatment. (D) Western blot analysis of HDAC1 expression in MKN45 cells and MKN28 cells treated with 10 nM or 20 nM miR-
520h mimics for 8 h. (E) The effect of 20 nM miR-520h mimics on the expression of the luciferase reporter under control of a HDAC1 30 untranslated region (30 UTR) was
determined by luciferase activity assay. All experiments were repeated three times. The asterisk indicates statistical signiﬁcance (P < 0.05) while ns indicates no statistical
signiﬁcance (P > 0.05).
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Fig. 4. Doxorubicin up-regulated expression of precursor miR-520h and primary miR-520h. (A) Precursor miR-520h expression in MKN45 and MKN28 cells after 4 lM
doxorubicin treatment for 8 h was analyzed by real-time RT-PCR. U6 snRNA served as loading control. B, Primary miR-520h expression in MKN45 and MKN28 cells after 4 lM
doxorubicin treatment for 8 h was analyzed by real-time RT-PCR. GAPDH served as loading control. All experiments were repeated three times. The asterisk indicates
statistical signiﬁcance (P < 0.05) while ns indicates no statistical signiﬁcance (P > 0.05).
Fig. 5. Up-regulation of HDAC1 enhanced drug resistance to doxorubicin. The viability inhibitory effect of doxorubicin on MKN45 (A and C) and MKN28 (B and D) cells before
and after exogenous HDAC1 expression (A and B) or 50 nM miR-520 inhibitor treatment (C and D) were determined by MTS assay. All experiments were repeated for three
times. The asterisk indicates statistical signiﬁcance (P < 0.05) while ns indicates no statistical signiﬁcance (P > 0.05).
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tor (Fig. 3E, left panel). A mutant plasmid that contains point muta-
tions at 3 nucleotides within the miR-520h binding site was also
constructed. The expression of luciferase driven by the wild-type
HDAC1 30-UTR was signiﬁcantly down-regulated by 20 nM miR-
520h mimics (P < 0.05) (Fig. 3E, right panel). In contrast, miR-
520h mimics had no effects on the expression of luciferase with
mutated HDAC1 30-UTR (P > 0.05). This result indicated that
HDAC1 is directly targeted by miR-520h.
2.4. Doxorubicin up-regulates expression of precursor miR-520h and
primary miR-520h
The upregulation of microRNAs could be attributed to enhanced
gene transcription or increased efﬁcacy of microRNA maturationfrom primary microRNA transcripts. Therefore, we examined the
precursor and primary miR-520h expression after 4 lM doxorubi-
cin treatment. Real-time PCR revealed that doxorubicin caused an
increase of precursor miR-520h similar to mature miR-520h
(Fig. 4A). Similarly, primary miR-520h was also upregulated after
doxorubicin treatment (Fig. 4B), indicating that doxorubicin upreg-
ulated miR-520h expression by promoting the transcription rather
than the maturation of miR-520h.
2.5. HDAC1 reduces the sensitivity of cancer cells to doxorubicin
Next, we tried to elucidate the relevance of HDAC1 protein
down-regulation to doxorubicin-induced anti-cancer effects in
gastric cancer cells. The effect of exogenous HDAC1 protein expres-
sion on the viability inhibition induced by doxorubicin was
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up-regulated (conﬁrmed byWestern blot analysis, data not shown)
by transfection with HDAC1 expressing plasmid for 48 h. As shown
in Fig. 4A and B, up-regulation of HDAC1 attenuated viability inhi-
bition induced by doxorubicin. Furthermore, miR-520h inhibitor,
similar to exogenous HDAC1, impaired doxorubicin-induced via-
bility inhibition (Fig. 5C and D). These results indicated that
changes in HDAC1 expression are relevant to the anti-cancer effect
of doxorubicin.
2.6. HDAC1 reduces doxorubicin–DNA interaction
All results presented above indicated that changes in HDAC1
protein expression are relevant to the anti-cancer effect of doxoru-
bicin. In the next, we wonder how HDAC1 impacted on the re-
sponse of cancer cells to doxorubicin. Doxorubicin can directly
interact with double strand DNA to induce DNA damage and dis-
rupt genome replication and gene transcription [14]. We ﬁrst
determined the intracellular level of cH2AX, an early marker of
DNA damages, in doxorubicin-treated cells with or without exoge-
nous HDAC1 expression. As shown in Fig. 6A, the intracellular level
of cH2AX in both MKN45 and MKN28 cells were reduced in the
presence of exogenous HDAC1, indicating that HDAC1 attenuates
doxorubicin-induced DNA damage.
Since HDAC1 participates in chromosome condensation [15,16],
we speculated that HDAC1 may interfere with the interaction of
doxorubicin with the chromosome. Doxorubicin itself relieves a
particular ﬂuorescence at a particular ﬂuorescence (excitation
488 nm/emission 575 nm). When doxorubicin interacted into
DNA, its ﬂuorescence intensity of doxorubicin will decrease
accordingly [17–19]. Thus, we detected doxorubicin–DNA interac-
tion by measuring ﬂuorescence (excitation 488 nm/emission
575 nm) intensity with the ﬂow cytometry [20]. As shown in
Fig. 6B, ﬂuorescence intensity in MKN45 and MKN28 cells transfec-
ted with HDAC1 expressing plasmid were higher than ﬂuorescenceFig. 6. Up-regulation of HDAC1 reduced doxorubicin–DNA interaction. (A) Western b
expressing plasmid 48 h before doxorubicin treatment. (B) Flow cytometry analysis of
with or without HDAC1 expressing plasmid. The asterisks indicate statistical signiﬁcance
of data points generated from experiments. (C) Western blot analysis of cH2AX level in
treatment. All experiments were repeated three times. (D) Proposed Model: doxorubic
inducing the expression of HDAC1-targeting miR-520h.intensity in cells without exogenous HDAC1 expression, indicating
that exogenous HDAC1 indeed impaired doxorubicin–DNA interac-
tion. When miR-520h inhibitor was applied to rescue down-regu-
lation of HDAC1 after doxorubicin treatment, less cH2AX was
accumulated (Fig. 6C).3. Discussion
Although doxorubicin has been widely used as a chemotherapy
drug in cancer treatments for many years, molecular mechanisms
underlying its anti-cancer effect, side effects and drug-resistance
are not well deﬁned. Our studies demonstrated that doxorubicin
at therapeutic concentration will epigenetically reduce HDAC1
expression to accelerate DNA damage, and forced expression of
HDAC1 will help gastric cancer cells to escape from doxorubicin-
induced DNA damage and subsequent cell death.
By deacetylating histones and other cancer-related proteins
[21], HDAC1 has emerged as a crucial participant in the develop-
ment of human cancers. Upregulation of HDAC1 is prevalent in var-
ious kinds of malignant tumors including gastric cancer [22–24].
Acetylation of histone would neutralize positive charge, resulting
in an open state of the chromatin [25]. Furthermore, HDAC1/2 di-
rectly interact with DNA topoisomerase II [15], an enzyme known
critical in chromatin organization [26]. Interestingly, DNA topoiso-
merase II can also be inhibited by doxorubicin. Clinical trials of
combined HDACi and doxorubicin in advanced solid tumors indi-
cate synergized effect of HDAC inhibitor and doxorubicin. In the
current study, we found that doxorubicin induces HDAC1 down-
regulation speciﬁcally, thus loosing chromatins to expose more po-
tential doxorubicin binding sites (Fig. 6). When doxorubicin in-
duced down-regulation of HDAC1 is rescued by exogenous
HDAC1 expression, DNA double strand damage is decreased
accordingly. Therefore, the upregulation of HDAC1 may lead to
the resistance to doxorubicin. Indeed, it has been demonstratedlot analysis of cH2AX level in MKN45 and MKN28 transfected with ﬂag-HDAC1
ﬂuorescence intensity in doxorubicin-treated MKN45 and MKN28 cells transfected
(P < 0.05). All experiments were repeated for three times. Error bars represent the SD
MKN45 and MKN28 preincubated with miR-520h inhibitor 48 h before doxorubicin
in downregulates HDAC1 expression to aggravate DNA-doxorubicin interaction by
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tent inhibitors of HDAC1 can synergize with doxorubicin to inhibit
the expression and activity of HDAC1 and exacerbate DNA damage
to induce cell death. Moreover, HDAC1 inhibitors may also be used
as the second line treatment for the patients with drug-resistance
to doxorubicin and HDAC1 upregulation might be the indicative
biomarker for such target therapies.
MicroRNAs (miRNAs) mediate gene silencing by binding the 30
or 50 untranslated regions (UTRs) of its target mRNA. Abnormal
expression of miRNAs contribute to the development of human
cancers [27–29]. MiRNAs are also implicated in the regulation of
DNA damage response by targeting checkpoint proteins [30,31].
Cellular survival and checkpoint response after DNA damage were
severely affected once miRNA-mediated gene-silencing was inhib-
ited. For example, miR-185 enhances radiation-induced apoptosis
and inhibition of proliferation by repressing ATR pathway.
Moreover, several miRNAs have been proved to regulate
chemosensitivity in cancer cells [32]. For example, miR-129 pro-
motes apoptosis and enhances sensitivity of colorectal cancer cells
to 5-ﬂuorouracil [33]. In this study, we ﬁnd a new miRNA to regu-
late DNA damage response and drug sensitivity. MiR-520h is up-
regulated by doxorubicin to target HDAC1 and sensitizes gastric
cancer cells to doxorubicin (Fig. 6).
The sensitivity of cancer cells to doxorubicin can be regulated by
some knownmiRNAs such asmiR-451 [34], indicating that induction
or activation of such miRNAs might be the potential approach to
improve the clinical efﬁcacy of doxorubicin based treatment.
Certainly, the result of this in vitro study should be conﬁrmed
in vivo. In addition, although MTT or MTS based cell viability
assays have been widely used to evaluate the growth inhibitory ef-
fect of doxorubicin, other examinations on cell cycle or cell death
should be performed to investigate the inhibition effect of doxoru-
bicin on cell growth.
In summary, doxorubicin down-regulates HDAC1 expression to
aggravate DNA–doxorubicin interaction by inducing the expres-
sion of HDAC1-targeting miR-520h. The upregulation of HDAC1
may contribute to drug resistance of human cancer cells and
targeting HDAC1 is a promising strategy to increase the clinical
efﬁcacy of DNA damage-inducing chemotherapeutic drugs.4. Materials and methods
4.1. Cell culture and doxorubicin treatment
MKN45 and MKN28 human gastric cancer cells were obtained
from RIKEN BioResource center (Ibaraki, Japan). MKN45 repre-
sented the poorly differentiated gastric cancer cells and MKN28
represented the well differentiated cells. MKN45 cells were cul-
tured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) with
10% fetal bovine serum and MKN28 cells were cultured in DMEM
medium (Invitrogen) with 10% fetal bovine serum. Both of them
were incubated at 5% CO2, 37 C, and 95% humidity. In the cell via-
bility analysis, cells were cultured with 0.25 lM, 0.5 lM, 1 lM,
2 lM and 4 lM doxorubicin respectively for 24 h, 48 h, 72 h. In
the Western blot analyses, cells were cultured with 4 lM doxoru-
bicin for 8 h.
4.2. Cell viability assay (MTS)
Cell viability was determined by CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay kit (Promega, Madison, WI,
USA). The cell viability was measured following instructions
provided [35] by using a colorimetric method with 3-(4,5-dimeth-
ylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS).4.3. Western blotting
Cell lysates harvested by 1  SDS–PAGE sample buffer (120 mM
Tris–HCl, pH 6.8, 4% SDS, 50 mM DTT, 2% glycerol and 0.01% bro-
mophenol blue). The same amount of protein from each lysate
was boiled for 10 min. The boiled lysates were resolved by SDS–
PAGE, transferred to PVDF membranes. Then the membranes were
incubated with the primary antibodies and corresponding second
antibodies. Digital images were acquired with enhanced chemilu-
minescence from Millipore (Billerica, MA, USA). Anti-GAPDH anti-
bodies were obtained from Cell Signaling Technology (Boston, MA,
USA). Anti-HDAC1, anti-HDAC2 and Anti-cH2AX antibodies were
from Millipore. Anti-HDAC3 antibodies were from Epitomics (Bur-
lingame, CA, USA). Anti-HDAC 8 antibodies were from Proteintech
(Chicago, IL, USA). Anti-Flag antibodies were from Sigma (St. Louis,
MO, USA). Laser density quantiﬁcation was performed by Quantity
One.
4.4. Plasmid transfection
Flag-HDAC1 plasmid was obtained from Gene Copoecia (Rock-
ville, MD, USA). Cells were seeded overnight in six-well plates
(2  105/well) and 2 lg of plasmids were transfected with FuGENE
HD (Roche Applied Science, Mannheim, Germany). Cells were
transfected for 48 h in six-well plates, and then transferred into a
96-well plate to pre-incubated with doxorubicin for 24 h before
analyzed by MTS assay. For other analyses, cells were harvested
for protein extraction after indicated timings.
4.5. RNA isolation and quantitative RT–PCR
Total RNA were isolated from cells grown in six-well plates and
pre-incubated with doxorubicin for 8 h to characterize HDAC1
mRNA expression and miR-520h expression in MKN45 and
MKN28 cells. The TRIzol RNA extraction kit (Invitrogen) was used
for mRNA extraction and miRNeasy Mini Kit (Qiagen, Hilden, Ger-
many) for microRNA extraction Total RNA was isolated using the
TRIzol RNA extraction kit (Invitrogen) and microRNAwas extracted
RNA concentrations were quantiﬁed by NanoDrop 1000 (Nano-
drop, Wilmington, Del, USA). The RNA integrity was evaluated by
agarose gel electrophoresis in addition to Nanodrop analysis.
Moreover, we designed primers for RT-PCR in different exons so
that DNA contamination should not be a concern. Reverse tran-
scription reaction was performed using 1 lg of total RNA with High
Capacity cDNA Reverse Transcription kit (Applied Biosystems, Fos-
ter City, CA, USA) or miScript miRNA detection system (Qiagen).
Real-time quantitative RT-PCR was performed using SYBR Green
Real-Time PCR System (Applied Biosystems). Human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) or U6 was used as an
internal control for mRNA or miRNA quantiﬁcation. Real-time
quantitative RT-PCR for miRNAs was detected by SYBR Green miS-
cript System (Qiagen). Primers used for RT-PCR were listed in
Table 1.
4.6. Luciferase activity assay
HDAC1 30 UTR fragments with wild or mutant miR-520h bind-
ing sites were cloned by PCR. Primers used were included in Ta-
ble 1. PCR products were inserted into pMD18T vector (Takara,
Dalian, LN, China) for sequence validation. The correct insert was
sub-cloned into pMIR-REPORT Luciferase vectors (Applied Biosys-
tems). Cells (1  105) were transfected with different pMIR-RE-
PORT Luciferase vectors into MKN45 cells in the absence or
presence of miR-520h mimics. 48 h after transfection, the activities
of ﬁreﬂy luciferase and renilla luciferase were measured using the
Dual-Glo™ luciferase assay system (Promega, USA) in accordance
Table 1
Primers used in this study.
Primers
hHDAC1-F GGTTCTGTGGCAAGTGCTGT
hHDAC1-R CTTGGCGTGTCCTTTGATAG
hMIR-511 GTGTCTTTTGCTCTGCAGTC
hMIR-449a GGCAGTGTATTGTTAGCTGGT
hMIR-583 CAAAGAGGAAGGTCCCATTAC
hMIR-570-3p CGAAAACAGCAATTACCTTTGC
hMIR-526a TCTAGAGGGAAGCACTTTCTG
hMIR-578 CTTCTTGTGCTCTAGGATTGT
hMIR-548b-3p CAAGAACCTCAGTTGCTTTTGT
hMIR-520g ACAAAGTGCTTCCCTTTAGAGTGT
hMIR-519c-5p CTCTAGAGGGAAGCGCTTTC
hMIR-512-5p CACTCAGCCTTGAGGGCAC
hMIR-410 AATATAACACAGATGGCCTGT
hMIR-520h ACAAAGTGCTTCCCTTTAGAGT
HDAC1-30 UTR-F GGACTAGTCCAGGGACAGAAACCAAG
HDAC1-30 UTR-R GCGAAGCTTGGAGAAGACAGACAGAGGG
HDAC1-30 UTR-mutant-F CTTGCCACCCATTCTTCCCGTTCTTAAAGGTGAAC
CATAAAGGGTGC
HDAC1–30 UTR-mutant-R GCACCCTTTATGGTTCACCTTTAAGAACGGGAAGA
ATGGGTGGCAAG
Precusor miR TCCCATGCTGTGACCCTCTAG
Primary miR TTCTGGATTCCAGAAAATATGC
Primary miR TCCCAAACAGTAACTCTAAAGG
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normalized with renilla luciferase activity and comparison
between wild and mutant pMIR-REPORT Luciferase vector was
made [29].
4.7. Flow cytometry analysis
Cells were washed twice with cold 1  PBS and then suspended
in 1  PBS at a concentration of 1  106 cells/ml. The samples were
then sent out for analysis by ﬂow cytometry (excitation 488 nm/
emission 575 nm) immediately. The normalized mean ﬂuorescence
intensity was calculated as (c – a)/(d  b) [20]. (a) Fluorescence
intensity of positive-ﬂuorescence cells without doxorubicin
treatment, without transfected with HDAC1 expressing plasmid
(represented for background ﬂuorescence intensity of HDAC1
low-expressed cells). (b) Fluorescence intensity of positive-ﬂuores-
cence cells without doxorubicin treatment, with transfected with
HDAC1 expressing plasmid for 48 h (represented for background
ﬂuorescence intensity of HDAC1 high-expressed cells). (c) Fluores-
cence intensity of positive-ﬂuorescence cells with doxorubicin
treatment, without transfected with HDAC1 expressing plasmid.
(d) Fluorescence intensity of positive-ﬂuorescence cells with
doxorubicin treatment, with transfected with HDAC1 expressing
plasmid for 48 h.
4.8. Statistical analysis
Data were presented as the mean ± S.D. from at least three inde-
pendent experiments. Unless speciﬁcally indicated, the non-para-
metric Mann–Whiney test was used for a comparison between
two groups. P < 0.05 indicates statistical signiﬁcance.
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